首页> Proceedings of the National Academy of Sciences of the United States of America> Heterogeneity in refractory acute myeloid leukemia.

Heterogeneity in refractory acute myeloid leukemia.

导出 OA

翻译打印收藏纠错

第一作者： Sachi,Horibata

第一单位： Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; sachi.horibata@nih.gov mgottesman@nih.gov hourigan@nih.gov.

作者： Sachi,Horibata ^[1] ; Gege,Gui ^[2] ; Justin,Lack ^[3] ; Christin B,DeStefano ^[4] ; Michael M,Gottesman ^[1] ; Christopher S,Hourigan ^[5]

作者单位： Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; sachi.horibata@nih.gov mgottesman@nih.gov hourigan@nih.gov. ^[1] Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20814. ^[2] NIAID Collaborative Bioinformatics Resource, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.;Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD 21702. ^[3] Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20814.;Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814. ^[4] Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20814; sachi.horibata@nih.gov mgottesman@nih.gov hourigan@nih.gov. ^[5]

关键词 acute myeloid leukemia cancer heterogeneity drug resistance